Strategic Plan Objective Detail
Interagency Autism Coordinating Committee (IACC) logo
Office of Autism Research Coordination (OARC) logo

Question 4: Short-term Objective B  

$23,229,501.04
Fiscal Year: 2010

Green dot: Objective has greater than or equal to the recommended funding.4SB. Standardize and validate at least 20 model systems (e.g., cellular and/or animal) that replicate features of ASD and will allow identification of specific molecular targets or neural circuits amenable to existing or new interventions by 2012. IACC Recommended Budget: $75,000,000 over 5 years.

Download 2010 Question 4: Short-term Objective B projects (EXCEL)
Note: Initial Sort is by Principal Investigator. Sorting by other columns is available by clicking on the desired column header.
Project Title Principal Investigator Institution
High-resolution diffusion tensor imaging in mouse models relevant to autism Poptani, Harish University of Pennsylvania
Behavioral and physiological consequences of disrupted Met signaling Levitt, Pat University of Southern California
Animal model of speech sound processing in autism Kilgard, Michael University of Texas at Dallas
Shank3 mutant characterization in vivo Kouser, Mehreen University of Texas Southwestern Medical Center
Identifying impairments in synaptic connectivity in mouse models of ASD Speed, Haley University of Texas Southwestern Medical Center
Novel genetic animal models of autism Powell, Craig University of Texas Southwestern Medical Center
Neuroligin function in vivo: Implications for autism and mental retardation Powell, Craig University of Texas Southwestern Medical Center
Animal models of autism: Pathogenesis and treatment Powell, Craig University of Texas Southwestern Medical Center
Deriving neuroprogenitor cells from peripheral blood of individuals with autism Fujinami, Robert University of Utah
Evaluation of altered fatty acid metabolism via gas chromatography/mass spectroscopy and time-of-flight secondary ion mass spectroscopy imaging in the propionic acid rat model of autism spectrum disorders MacFabe, Derrick University of Western Ontario
Transgenic mouse model to address heterogeneity in autism spectrum disorders Blakely, Randy Vanderbilt University
Murine genetic models of autism Veenstra-Vanderweele, Jeremy Vanderbilt University
Mouse genetic model of a dysregulated serotonin transporter variant associated with autism Veenstra-Vanderweele, Jeremy Vanderbilt University
Using zebrafish and chemical screening to define function of autism genes Sive, Hazel Whitehead Institute for Biomedical Research
Caspr2 dysfunction in autism spectrum disorders Robbins, Elissa Yale University
Integrated approach to the neurobiology of autism spectrum disorders Vaccarino, Flora Yale University
Cellular and genetic correlates of increased head size in autism spectrum disorder Vaccarino, Flora Yale University

Objective Cumulative Funding Table

IACC Strategic Plan Objective 2008 2009 2010 2011 2012 Total
Standardize and validate at least 20 model systems (e.g., cellular and/or animal) that replicate features of ASD and will allow identification of specific molecular targets or neural circuits amenable to existing or new interventions by 2012.

IACC Recommended Budget: $75,000,000 over 5 years
4.5
$15,879,827
42 projects

4.S.B
$20,162,709
70 projects

4.S.B
$23,229,501
92 projects

4.S.B
$21,606,118
89 projects

4.S.B
$21,232,514
94 projects

$102,110,669
4.S.B. Funding: The recommended budget was met. Significantly more than the recommended minimum budget was allocated to projects specific to this objective.

Progress: More than 90 projects were supported to develop animal models.

Remaining Gaps, Needs, and Opportunities: Planning Group members discussed whether the amount of investment in this area is appropriate when compared to investments in clinical trials and other later stage studies. Invited experts suggested that the current stage of scientific research in ASD requires pre-clinical research to identify targets from animal and cellular models. Similar to cancer treatment development pathways, which spanned 20-30 years, research in ASD must invest in model systems to understand the fundamental biology from which translation to the clinic can be built. The translational validity of research in non-human animals cannot be determined until human trials are conducted, thus the need for rapid progress to clinical studies in humans is important.